Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Arrowhead Pharmaceuticals's Plozasiran sodium?
Plozasiran sodium is an antisense rnai oligonucleotide commercialized by Arrowhead Pharmaceuticals, with a leading Phase III program in Hypertriglyceridemia. According...
Plozasiran sodium by Arrowhead Pharmaceuticals for Hypertriglyceridemia: Likelihood of Approval
Plozasiran sodium is under clinical development by Arrowhead Pharmaceuticals and currently in Phase III for Hypertriglyceridemia. According to GlobalData, Phase...
Plozasiran sodium by Arrowhead Pharmaceuticals for Familial Chylomicronemia (Type I Hyperlipoproteinemia): Likelihood of Approval
Plozasiran sodium is under clinical development by Arrowhead Pharmaceuticals and currently in Phase III for Familial Chylomicronemia (Type I Hyperlipoproteinemia)....